Idit Shachar 25/5/15 1

CURRICULUM VITAE

Idit Shachar, Ph.D.

Incumbent of the Dr. Morton And Anne Kleiman

Professorial Chair

Head, Department of Immunology

Weizmann Institute

Rehovot, Israel 76100

PERSONAL DETAILS

Place and date of birth: Israel, September 4th 1964

Marital status: Married with two children (16, 8)

Military service: 1982-1984, second lieutenant

Contacts: Phone: 08-9344257

E-mail: idit.shachar@weizmann.ac.il

Home page: http://www.weizmann.ac.il/immunology/IditShachar/

EDUCATION

1993-1997 Post doctoral fellow with Dr. R.A. Flavell, Yale School of Medicine.

1989-1993 Ph.D., Biochemistry

Tel-Aviv University, The George S. Wise Faculty of Life Sciences.

Thesis title:

"The Molecular Basis for Sorting, Transport and Secretion of IgM" under the

supervision of Dr. Shoshana Bar-Nun.

1987-1989 M.Sc., with honor, Biochemistry

Tel-Aviv University, The George S. Wise Faculty of Life Sciences, under the

supervision of Dr. Shoshana Bar-Nun.

1984-1987 B.Sc., with honor, Biology

Tel-Aviv University, The George S. Wise Faculty of Life Sciences.

Idit Shachar 25/5/15 2

EMPLOYMENT HISTORY

2013-present Full Professor in the Department of Immunology, The Weizmann Institute of

Science.

2004- 2013 Associate Professor in the Department of Immunology, The Weizmann institute of

Science.

1998-2004 Senior Scientist in the Department of Immunology, The Weizmann institute of

Science.

1989 Guest scientist with Dr. R. Fine, Boston University

Medical Center (four months)

OTHER APPOINTMENTS

2014- Chair, 2015 EMBO-ESF on B cells

2014- President of the Israel Immunological Society

2014- Head, department of Immunology

2012-2013 Vice-chair, 2013 EMBO-ESF on B cells

2012-2014 Vice president of the Israel Immunological Society

2009-2014 Head of the theses committee

2006-2014 Treasurer of the Israel Immunological Society

Membership in National and International Academic Committees and Societies

2007-2014 Member in the Katzir Fellowship committee.

2006-2014 Member in the Theses committee.

2007-2010 Member in the FEBS fellowship committee.

2007-2010 Member in the Research and Administration Service Committee.

1998-present American association of Immunologists, Board Member.

1998-present Israel Immunological Society, Board Member

Membership in scientific advisory boards and consulting activities

2008-2010 Consulting to CytoD, Meytav technology incubator

Idit Shachar 25/5/15 3

Teaching

1998- present Faculty courses in Immunology, teaching the B cell part.

1999-2002 Annual advanced Laboratory Course, The Weizmann Institute of Science.

RECOGNITION

Prizes and Awards

2005 Incumbent of the Dr. Morton and Anne Kleiman Professorial Chair.

2003 Teva prize for excellent research

2001 ISF prize for advancing education and science.

2000 Incumbent of The Alvin and Gertrude Levine Career Development Chair of Cancer

Research

1997 Alon foundation, young scientist fellowship.

1995-1998 Irvington Institute for Medical Research. USA. Post-Doctoral Fellowship

1993-1994 Rothschild foundation, Israel. Post-Doctoral Fellowship

1993 Wolf Foundation award.

1991 ASCB meeting, Travel award.

1989-1993 Faculty of Life Sciences, Tel-Aviv University, Dean's Graduate award.

1983-1988 Dean’s honor.

International Conferences organizing committees

2015 EMBO-ESF conference: ”Be There Or Die? The Role Of The

Microenvironment In B Cell Behaviour In Health And Disease” Spain

2015 FEBS workshop: “ Inflammation, the bonfire from within”, Israel

2015 MIF international meeting

2015 Annual meeting of the Israel Immunological Society

2013 EMBO-ESF conference: ” B cells from bedside to bench and back” , Poland

2012 FEBS workshop: “Decisions in the life of immune cells”, Israel

2010 The 32nd Annual Katzir-Katchalsky conference: “Immunity in context”, Israel.

2007 Annual meeting of the Israel Immunological Society

Idit Shachar 25/5/15 4

Invited Lectures and Chairmanship in International Scientific Meetings and seminars (five

years)

2015 1. FEBS workshop: “ Inflammation, the bonfire from within”, Weizmann Institute,

Rehovot, Israel. Organizer and speaker.

2. International MIF meeting, Rehovot, Israel, organizer and speaker.

3. “B cells: Immunity and Autoimmunity“, Erlangen, Germany- Invited speaker.

4. Richard Flavell 70’s birthday. Invited speaker.

5. Eurpean congress of Immunology 2015. Workshop’s chair.

6. EMBO-ESF conference: ”Be There Or Die? The Role Of The Microenvironment

In B Cell Behaviour In Health And Disease” Spain. Chair and speaker.

7. Annual meeting of the Israel Immunological Society- Organizer.

8. ISF workshop- “Prospects of Immunity for Precision Cancer Medicine,

Jerusalem, Israel. Invited speaker.

9. The 2nd Joint Symposium of the Trinity Biomedical Sciences institute and the

Weizmann institute of Science- Organizer and speaker.

2014 1. Ilanit 2014- session chair and speaker.

2. International MIF meeting, Lausanne, Switzerland-invited speaker.

3. 3rd excellence in Midkine research conference, Kyoto, Japan-invited speaker.

4. "Inflammation and cancer- fast moving fields inbiomedicine yielding new

therapies", Dublin, Ireland- Invited speaker.

2013 1. ESF-EMBO:” B cells from bedside to bench and back”, Poland, Co-chair and a

speaker.

2. National Human Genome Research Institute, NIH, Bethesda, MD.

3. Weizmann-Karolinska Institute Symposium: Weizmann Institute, Rehovot,

invited speaker.

2012 1. IUBMB and FEBS 2012 Congress, Seville, Spain. Invited symposium speaker.

2. FEBS meeting:” Decisions in the life of immune cells” Israel, Organizer and

speaker.

Idit Shachar 25/5/15 5

3. 2nd excellence in Midkine research conference, Istanbul, Turkey. Invited Speaker.

4. “International MIF symposium” Louisville, KT, USA. Invited speaker.

5. “MIF in Health and Disease” Mumbai, India, Invited speaker.

6. Annual meeting of the Israel Immunological Society. Chair

2011 1. ESF-EMBO: B cells and Protection: Back to Basics, Spain. Invited speaker.

2. Manchester-Weizmann meeting, Manchester, England. Invited speaker.

3. Department of experimental Immunology and Hematology, the Academic

Medical Center Amsterdam, University of Amsterdam, the Netherlands

4. “International MIF symposium” New-Haven, CT, U.S.A. Invited speaker.

5. First French-Israeli International Meeting on B cells and Therapeutic

Antibodies, Jerusalem, Israel. Invited Speaker.

6. Second meeting on B cells and Autoimmunity, Haifa, Israel. Invited Speaker.

2010 1. Strasburg-Weizmann symposium. Weizmann Institute, Rehovot, Israel.

2. Department of Lymphoma/Myeloma, The University of Texas MD

Anderson Cancer Center, Houston Texas, U.S.A.

3. “Immunity in context” Weizmann Institute, Rehovot, Israel. Organizer and

speaker.

4. 6th International Symposium on “Cytokine Signaling” Aachen, Germany.

Invited speaker.

2009 1. Keystone meeting: “B cells in context”. Workshop speaker.

2. Marie Curie conference: ”Immunology of HIV and TB infection”

Stockholm, Sweden, invited speaker.

3. DFG sponsored Collaborative Research Center on Immunodeficiency (SFB

620): “New Developments in Immunodeficiency Research” Freiburg,

Germany, invited speaker.

4. Department of Pathology and Laboratory Medicine, Weill Medical College

of Cornell University, New York, U.S.A.

5. “International MIF symposium” Schloß Hochhausen, Germany, invited

speaker.

Idit Shachar 25/5/15 6

6. “The essential role of B cells in autoimmune diseases”, Technion, Haifa

Israel. Invited speaker.

2008 1. McGill Weizmann symposium: “Cancer-a cellular and molecular view”,

Rehovot, Israel, Invited speaker.

2. New York University School of Medicine, Skirball Institute of

Biomolecular Medicine, NY, U.S.A.

3. Laboratory for Immunological and Molecular Cancer Research, LIMCR

Federal Hospital Salzburg, Salzburg, Austria

SCIENTIFIC PRODUCTIVITY

Competitive National and International Grants (last 5 years)

Years Agency Sum

2015-2018 DKFZ-IMOS 130,000 Euro

2014-2017 BSF 90,000$

2014-2015 Merck 300,000 Euro

2012-2014 ICRF 60,000$

2011-2013 Kamin 200,000$

2011-2015 Israel Science Foundation 200,000$

2011-2012 Israel Cancer Association 50,000$

2009-2011 Israel Science Foundation 100,000$

2008-2011 Israel Science Foundation-Morasha 150,000$

2007-2010 Minerva 150,000$

2005-2008 EU 50,000 Euro

2005-2006 Israel Cancer Association 10,000$

2005-2008 Israel Science Foundation 120,000$

2004-2008 EU 90,000 Euro

Idit Shachar 25/5/15 7

Present and former graduate students and staff

Name Years Position

Lital Server 2014-2016 postdoc

Hadas Lewinsky 2014-2015 M.Sc.

Avital Barak 2014-2018 Ph.D.

Lihi Radomir 2013-2017 Ph.D.

Mattias Kramer 2013-2015 postdoc

Naama Gil 2012-2016 Ph.D.

Maya Yaskovich-Gordin 2012 postoc

Nimrod Hazan 2011-2012 M.Sc.

Inbal Binsky 2010-2011 postdoc

Ezster Bakos 2010-2015 Ph.D.

Ayelet Marom 2009-2014 Ph.D.

Yoni Lati 2008-2009 M.Sc.

Sivan Cohen 2008-2012 Ph.D.

Einat Zelman 2006-2011 Direct Ph.D.

Maya Yaskovich 2006-2011 Direct Ph.D.

Inbal Binsky 2005-2010 Direct Ph.D.

Anita Sapoznikov 2005-2009 Ph.D.

Tamar Avin 2005-2006 M.Sc.

Shirly Becker-Herman 2004-2005 postdoc

Yael Gore 2004-2009 Ph.D.

Galit Arie 2002-2003 M.Sc.

Helena Medvedovsky 2002-2003 M.Sc.

Gili Hart 2002-2007 Ph.D.

Gili Hart 2001-2002 M.Sc.

Liat Flaishon 2000-2004 Ph.D.

Anat Kerem-Angel 1999-2002 postdoc

Shirly Becker-Herman 1999-2004 Ph.D.

Didi Matza 1998-2002 Ph.D.

Idit Shachar 25/5/15 8

Referee for research grants and journals

Grants: Swiss Science Foundation; French National Research Agency; Germany-

Israel Foundation (GIF); Israel Cancer Association; Israel Ministry of

Health; Israel Science Foundation (ISF); United States-Israel Binational

Science Foundation (BSF)

Journals: Immunity, Blood, Proc. Natl. Acad. Sci U.S.A., Journal of Immunology,

European Journal of Immunology, Journal of Biochemical Chemistry,

Journal of Leukocyte Biology, Hepatology, Journal of Internal Medicine,

Haematologica, Clinical Cancer Research, International Immunology,,

FEBS Letters, Immunology letters, Steroids, Mediators of Inflammation.

Idit Shachar 25/5/15 9

PATENTS

1. “Method and Pharmaceutical composition for treating inflammation” United States patent

No. 6,911,198, granted June 28th, 2005.

2. “CCL2, as an anti-inflammatory compound for the treatment of inflammation”. In

registration process in the USA patent office.

3. “CD84 as a survival receptor in tumor cells”. In registration process in the USA patent

office.

4. “Methods for treating inflammation; CD151 as a regulator of T cell homing and

inflammation”. In registration process in the USA patent office.

5. “CD151 extracellular domain as a blocker of CD151 activity and inflammation”. In

registration process in the USA patent office.

I. Languages

Hebrew 3

English 3

Idit Shachar 25/5/15 10

List of Publications:

1. Amitay R., Bar-Nun S., Haimovitch J., Rabinovitch E. and Shachar I. (1991) “Post-

Translational Regulation of IgM Expression in B lymphocytes”. J. Biol. Chem. 266:

12568-12572.

2. Morin P.J., Johnson R.J., Shachar I., Fine R.E. and Leeman S.E. (1991)

“Characteristics of Tachykinin Transport Vesicles in the Optic Nerve”. Ann. NY.

Acad. Sci. 632: 442-443.

3. Shachar I., Amitay R., Rabinovitch E., Haimovitch J. and Bar-Nun S. (1992)

“Polymerization of Secretory IgM in B Lymphocytes is Prevented by a Preceding

Targeting to a Degradation Pathway” .J. Biol. Chem. 267: 24241- 24247.

4. Amitay R., Shachar I., Rabinovitch E., Haimovitch J. and Bar-Nun S. (1992)

“Degradation of Secretory IgM in B Lymphocytes Occurs in a post-Endoplasmic

Reticulum Compartment and is Mediated by a Cysteine Protease”. J. Biol. Chem. 267:

20697-20700.

5. Rabinovitch E., Bar-Nun S., Amitay R., Shachar I., Gur B., Taya M. and Haimovitch

J. (1993) “Different Assembly Species of IgM are Directed to Distinct Degradation

Sites Along the Secretory Pathway”. J. Biol. Chem. 268: 24145-24148.

6. Shachar I., Rabinovitch E., Kerem A. and Bar-Nun S. (1993) “Thiol Reducing

Agents and Calcium Perturbants Alter the Intracellular Sorting of IgM”. J. Biol.

Chem. 269: 27344- 27350.

7. Shachar I., Elliott E.A., Chasnoff B., Grewal I.S. and Flavell R.A. (1995)

“Reconstitution of Invariant Chain Function in transgenic Mice in vivo by Individual

p31 and p41 Isoforms”. Immunity 3: 373-383.

Idit Shachar 25/5/15 11

8. Winitz D., Shachar I., Elkabetz Y., Samuelov M. and Bar-Nun S. (1996)

“Degradation of Distinct Assembly Forms of Immunoglobulin M Occurs in Multiple

Sites in Permeabilized B Cells”. J. Biol. Chem. 271: 27645-27651.

9. Shachar I. and Flavell R.A. (1996) “Invariant Chain is Required for B Cells

Maturation and Function”. Science 274: 106-108.

10. Pierre P*., Shachar I.*, Matza D., Gatti E., Flavell R.A. and Mellman I. (2000)

“Invariant Chain Controls H2-M Proteolysis in Mouse Splenocytes and Dendritic

Cells”. J. Exp. Med 191: 1057-1062.

*Pierre and Shachar contributed equally to this work.

11. Flaishon L., Hershkovitz R., Lantner F., Lider O., Alon R., Levo Y., Flavell R.A. and

Shachar I. (2000) ”Autocrine Secretion of Interferon g Negatively Regulates Homing

of Immature B Cells”. J. Exp. Med. 192: 1381-1387.

12. Matza D., Wolstein O., Dikstein R. and Shachar I. (2001) “Invariant Chain Induces B

Cell Maturation by Activating TAFII105-NF-B Dependent Transcription Program”.

J. Biol. Chem. 276: 27203-27206.

13. Flaishon L., Lantner F., Hershkovitz R., Levo Y. and Shachar I. (2001) “Low Levels

of IFN- Down-regulate the Integrin-Dependent Adhesion of B cells by Inhibition of

Cytoskeleton Rearrangement”. J. Biol. Chem. 276: 46701-46706.

14. Topilski I., Harmelin A., Flavell R.A., Levo Y. and Shachar I. (2002) “Preferential

Th1 Immune Response in Invariant Chain- Deficient Mice“. J. Immunol. 168: 1610-

1617.

15. Matza D., Lantner F., Bogoch Y., Flaishon L., Hershkovitz R. and Shachar I. (2002)

“Invariant Chain Induces B cell Maturation in a Process Which is Independent of its

Chaperonic Activity”. Proc. Natl. Acad. Sci U.S.A. 99: 3018-3023.

Idit Shachar 25/5/15 12

16. Silkov A., Wolstein O., Shachar I. and Dikstein R. (2002) “Enhanced Apoptosis of B

and T Lymphocytes in TAFII105 Dominant Negative Transgenic Mice is Linked to

NF-kappaB”. J. Biol. Chem. 277: 17821-17829.

17. Flaishon L., Topilski I., Shoseyov D., Hershkoviz R., Fireman E., Levo Y., Marmor

S., and Shachar I. (2002) “Anti-Inflammatory Properties of Low Levels of IFN-g”. J.

Immunol.: Cutting edge: 168: 3707-3711.

18. Becker-Herman S., Lantner F. and Shachar I. (2002) “Id2 Negatively Regulates B

cell Differentiation in the Spleen”. J. Immunol. 168: 5507-5513.

19. Schori H., Lantner F., Shachar I.*, and Schwartz M.* (2002) “Severe

Immunodeficiency has Opposite Effects on Neural Survival in Glutamate-Susceptible

and Resistant Mice: Adverse Effect of B Cells”. J. Immunol. 169: 2861-2865.

*Equal contribution

20. Matza D., Kerem A., Medvedovsky H., Lantner F. and Shachar I. (2002) “Invariant

chain induced B cell differentiation requires intramembrane - proteolytic release of the

cytosolic domain”. Immunity 17: 549-560.

21. Hart G., Flaishon L., Becker-Herman S. and Shachar I. (2003) “The Ly49D receptor

expressed on immature B cells regulates their interferon gamma secretion, actin

polymerization and homing”. J. Immunol. 171: 4630-4638.

22. Topilski I., Flaishon L., Naveh Y., Harmelin A., Levo Y. and Shachar I. (2004) “The

anti-inflammatory effects of 1,25-Dihydroxyvitamin D3 on Th2 cells in vivo are due

in part to the control of integrin-mediated T lymphocyte homing”. Eur. J. Immunol.

34: 1068-1076.

23. Flaishon L., Becker-Herman S., Hart G., Levo Y. Kuziel W.A. and Shachar I. (2004)

“Expression of the Chemokine Receptor CCR2 on Immature B cells Negatively

Regulates their Cytoskeleton Rearrangement and Migration”. Blood 104: 933-941.

Idit Shachar 25/5/15 13

24. Haran M., Chebatco S., Flaishon L., Lantner F., Harpaz N., Valinsky L. Berrebi A. and

Shachar I. (2004) “Grb7 expression and cellular migration in chronic lymphocytic

leukemia: a comparative study of early and advanced stage disease”. Leukemia

18:1948-1950.

25. Hart G., Flaishon L., Becker-Herman S. and Shachar I. (2005) “Tight regulation of

IFN- transcription and secretion in immature and mature B cells by the inhibitory

MHC class I receptor, Ly49G2”. J. Immunol. 175: 5034-5042.

26. Becker-Herman S., Arie G., Medvedovsky H., Kerem A. and Shachar I. (2005)

“CD74 is a member of the regulated intramembrane proteolysis (RIP) processed

protein family”. Mol. Biol. Cell 16:5061-5069.

27. Starlets D., Gore Y., Binsky I., Haran M., Harpaz N., Shvidel L., Becker-Herman S.,

Berrebi A. and Shachar I. (2006) “Cell Surface CD74 initiates a signaling cascade

leading to cell proliferation and survival” Blood 107: 4807-4816.

28. Wald O., Weiss I.D., Wald H., Shoham H., Bar-Shavit Y., Beyder K., Galun E., Weiss

L., Flaishon L., Shachar I., Nagler A., Lu B., Gerard C., Gao J.-L., Mishani E., Farber

J., and Peled A. (2006) “IFN-gamma Acts on T Cells to Induce NK Cell Mobilization

and Accumulation in Target Organs” J. Immunol. 176: 4716-4729.

29. Schori H., Shechter R., Shachar I. and Schwartz M. (2007) “Genetic manipulation of

CD74 in mouse strains of different backgrounds can result in opposite responses to

CNS injury” J. Immunol. 178: 163-171.

30. Hart G., Flaishon L. and Shachar I. (2007) “IL-12 and IL-18 downregulate B cell

migration in an Ly49D-dependent manner” Eur. J. Immunol.: 37: 1996-2007.

31. Binsky I., Haran M., Starlets D., Gore Y., Lantner F., Harpaz N., Leng L., Goldenberg

D.M., Shvidel L., Berrebi A., Bucala R., and Shachar I. (2007) “IL-8 secreted in a MIF

and CD74 dependent manner regulates B-CLL survival” Proc. Natl. Acad. Sci U.S.A.:

104: 13408-13413.

Idit Shachar 25/5/15 14

32. Lantner F., Starlets D., Gore Y., Flaishon L., Yamit-Hezi A., Dikstein R., Leng L.,

Bucala R., Machluf Y., Oren M. and Shachar I. (2007) “CD74 induces TAp63

expression leading to B cell survival” Blood 110: 4303-4311.

33. Hart G., Avin-Wittenberg T. and Shachar I. (2008) “IL-15 regulates immature B cell

homing in an Ly49D, IL-12, and IL-18 dependent manner” Blood 111: 50-59.

34. Gore Y., Starlets S., Maharshak N., Becker-Herman S., Kaneyuki U., Leng L., Bucala

R. and Shachar I. (2008) “Macrophage Migration Inhibitory Factor (MIF) Induces B

Cell Survival by Activation of a CD74/CD44 Receptor Complex” J. Biol. Chem 283:

2784-2792.

35. Sapoznikov A., Pewzner-Jung Y., Kalchenko V., Krauthgamer R., Shachar I.* and

Jung S.* (2008) “The Bone Marrow Immune Niche: Perivascular Dendritic cell

clusters provide critical B cell survival signals” Nat. Immunol.9: 388-395

(Commentaru in the same issue : Nagasawa T., (2008) “New niches for B cells” Nat.

Immunol. 9:345-346).

*Equal contribution

36. Flaishon L., Hart G., Zelman E., Moussion C., Grabovsky V., Lapidot Tal G.,

Feigelson S., Margalit R., Harmelin A., Avin- Wittenberg T., Shoseyov D., Alon R.,

Girard J.-P. and Shachar I. (2008) “Anti-inflammatory effects of an inflammatory

chemokine: CCL2 inhibits lymphocyte homing by modulation of CCL21 triggered

integrin-mediated adhesions” Blood 112: 5016-5025.

37. Hartmann TN., Grabovsky V., Wang W., Desch P., Rubenzer G., Wollner S., Binsky

I., Vallon-Eberhard A., Sapoznikov A., Burger M., Shachar I., Haran M.,

Honczarenko M., Greil R. and Alon R. (2009) “Circulating B-Cell Chronic

Lymphocytic Leukemia Cells Display Impaired Migration to Lymph Nodes and Bone

Marrow” Cancer Res 69: 3121-3130.

Idit Shachar 25/5/15 15

38. Berrih-Aknin S., Ruhlmann N., Bismuth J., Cizeron-Clairac G., Zelman E., Shachar

I., Dartevelle P., de Rosbo N.K., Le Panse R. (2009) “CCL21 overexpressed on

lymphatic vessels drives thymic hyperplasia in myasthenia” Ann Neurol. 66:521-31.

39. Maharshak N., Hart G., Ron E., Zelman E., Sagiv A., Arber N., Brazowski E.,

Margalit R., Elinav E., Shachar I. (2010) “CCL2 (pM levels) as a therapeutic agent in

inflammatory bowel disease models in mice” Inflammatory Bowl Diseases 16: 1496-

1504.

40. Maharshak N., Cohen S., Lantner F., Hart G., Leng L., Bucala R. and Shachar I.

(2010) “CD74 is a survival receptor on colon epithelial cells” World Journal of

Gastroenterology: 16: 3258-3266.

41. Binsky I., Lantner F., Grabovsky V., Harpaz N., Shvidel L., Berrebi A., Goldenberg

D.M., Leng L., Bucala R., Alon R., Haran M. and Shachar I. (2010) “TAp63

regulates VLA-4 expression and CLL cell migration to the BM in a CD74 dependent

manner” J. Immunol. 184: 4761-4769.

42. Gore Y., Lantner F., Hart G. and Shachar I. (2010) “Mad3 negatively regulates B cell

differentiation in the spleen by inducing Id2 expression” Mol. Biol. Cell 21: 1864-

1871.

43. Gordin M., Tesio M., Cohen S., Gore Y., Lantner F., Leng L., Bucala R. and Shachar

I. (2010) “c-Met and its ligand HGF regulate mature B cell survival in a pathway

induced by CD74” J. Immunol. 185: 2020-2031.

44. Manevich-Mendelson E., Grabovsky V., Feigelson S.W., Cinamon G., Gore Y.,

Goverse G., Monkley SJ, Margalit R, Melamed D., Mebius R.E., Critchley D.R.,

Shachar I., Alon R. (2010) “Talin1 is required for integrin-dependent B lymphocyte

homing to lymph nodes and the bone marrow but not for follicular B cell maturation in

the spleen” Blood 116: 5907-5918.

45. Lapter S., Ben-David H., Sharabi A., Zinger H., Telerman A., Gordin M., Leng L.,

Bucala R., Shachar I., Mozes E. (2011) “A role for the B-cell CD74/macrophage

Idit Shachar 25/5/15 16

migration inhibitory factor pathway in the immunomodulation of systemic lupus

erythematosus by a therapeutic tolerogenic peptide” Immunology 132: 87-95.

46. Cohen S., Shoshana O., Zelman-Toister, E., Maharshak N., Binsky- Ehrenreich I.,

Gordin M., Hazan-Halevy I, Herishanu Y., Shvidel L., Haran M., Leng L., Bucala R.,

Harroch S., Shachar I. (2012) “The Cytokine Midkine and its Receptor RPTP

Regulate B Cell Survival in a Pathway Induced by CD74” J. Immunol 188: 259-269.

47. Stepensky P., Keller B., Buchta M., Kienzler A.K., Elpeleg O., Somech R., Cohen

S., Shachar I., Miosge L.A., Schlesier M., Fuchs I., Enders A., Eibel H., Grimbacher

B., Warnatz K. (2013) “Deficiency of caspase recruitment domain family, member

11 (CARD11), causes profound combined immunodeficiency in human subjects” J.

Allergy Clin. Immunol. 131: 477-485.

48. Binsky-Ehrenreich I., Marom A., Sobotta M.C., Lantner F., Harpaz N., Shvidel L,

Berrebi A., Hazan-Halevy I., Herishanu Y, Aloshin A., Sagi I., Goldenberg D.M.,

Leng L., Bucala R., Haran M and Shachar I. (2014) “CD84 is a survival receptor for

CLL cells”. Oncogene 33: 1006-1016.

49. Klasen C., Ohl K., Sternkopf M., Shachar I., Schmitz C., Heussen N., Hobeika E.,

Levit-Zerdoun E., Tenbrock K., Reth M., Bernhagen J., El Bounkari O. (2014) “MIF

promotes B cell chemotaxis through the receptors CXCR4 and CD74 and ZAP-70

signaling” J. Immunol. 192: 5273-5284.

50. Zelman-Toister E., Bakos E., Cohen S., Zigmond E., Shezen E., Grabovsky V., Sagiv

A., Hart G., Kaushansky N., Ben-Nun A., Maharshak N., Sonnenberg A., Alon R.,

Becker-Herman S. and Shachar I. (2015) “CD151 regulates T cell migration and

homing in health and disease”. Inflammatory Bowel Diseases: In press

Invited reviews:

1. Matza D., Kerem A. and Shachar I. (2003) “Invariant chain, a chain of command”

Trends in Immunol. 24: 246-248.

Idit Shachar 25/5/15 17

2. Shachar I. and Haran M. (2011) “ The secret second life of an innocent chaperone:

The story of CD74 and B-cell/chronic lymphocytic leukemia (CLL) cell survival”.

Leukemia and lymphoma 52: 1446-14454.

3. Cohen S. and Shachar I. (2012) “Cytokines as regulators of proliferation and survival

of healthy and malignant peripheral B cells” Cytokine 60: 13-22.

4. Shachar I., Cohen S., Marom A. and Becker-Herman S. (2012) “Regulation of CLL

survival by hypoxia-inducible factor and its target genes” FEBS J. 586: 2906-2910.

5. Shachar I. and Karin N. (2013) “The dual roles of inflammatory cytokines and

chemokines in the regulation of autoimmune diseases and their clinical implications”

J. Leu Biol. 93: 51-61.

6. Cohen S., and Shachar I. (2014) “Midkine as a regulator of B cell survival in health

and disease” British Journal of Pharmacology.171: 888-895.

7. Bucala R. and Shachar I. (2015) “The integral role of CD74 in antigen presentation,

MIF signal transduction and B cell survival and homeostasis” Mini reviews in

Medicinal Chemistry. 14: 1132-1138.

Chapter in a book:

The MIF handbook: chapter “CD74, the natural receptor for MIF, regulates cell

survival in health and disease”. Word scientific press (2012).

Submitted papers:

Marom A, Barak A.F., Kramer M.P., Binsky-Ehrenreich I., Cohen S., Lewinsky H.,

Tsitsou-Kampeli A., Kalchenko V., Kuznetsov Y., Mirkin V., Dezorella N., Shapiro

M., Schwartzberg P.L., Cohen Y., Shvidel L., Haran M, Becker-Herman S.,

Herishanu Y. and Shachar I. (2015) “CD84 mediates CLL-microenvironment

interactions”.